These findings unveil a crucial interaction between histone marks and transcriptional modulation during the progression of TNBC, thereby supporting strategies targeting the KMT2D‐H3K4me1‐YBX1 axis to treat breast cancer. Here, KMT2D is linked to breast carcinoma.